Alexandre Loiseau

About Alexandre Loiseau

Alexandre Loiseau, also known as Sacha Loiseau, is the founder of Mauna Kea Technologies and remains the company’s key strategic leader. At this listed medical technology group, he currently serves as Chairman of the Board and Chief Executive Officer, a combined role he has held since October 2022, after having already served as Chairman since October 2018. His career has been closely tied to the development of Cellvizio, Mauna Kea’s probe-based confocal laser endomicroscopy platform, which he helped design, industrialize, and bring to market. According to company disclosures, he helped raise more than €120 million from private and public investors, including €56.5 million through the July 2011 listing on NYSE Euronext Paris. His profile combines scientific depth, industrial leadership, and listed-company governance experience. Alexandre Loiseau graduated from École Polytechnique and holds a Ph.D. in astrophysics and optical instrumentation from the University of Paris-Diderot. He began his career at CNES in Toulouse and the Paris Observatory before joining NASA’s Jet Propulsion Laboratory in California as a research scientist. This background at the intersection of advanced research and technology innovation has strongly shaped his approach to medtech development. He is also the author of multiple scientific publications and the holder of international patents, reinforcing his credibility in innovation-driven sectors. Beyond Mauna Kea Technologies, Alexandre Loiseau has contributed to the French medical technology ecosystem. He helped found Medtech in France, where he serves as Vice-President, and has mentored the Polytechnique-Stanford Ignite program for young medtech entrepreneurs. The company also notes that he was appointed co-leader of France’s Re-industrialization Plan for Medical Devices in 2013, underlining his influence in the broader industrial policy landscape. More recently, he has been associated with Mauna Kea’s partnership strategy, intellectual property expansion, and strategic repositioning, including AI-enabled endomicroscopy initiatives and new commercial collaborations.